Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30668738 | 1.00 | HSD17B1 (0.44) | HSD17B1STSPAX8P2RX7POLB | |
| SCHEMBL1445867 | 0.84 | PAX8 (0.38) | PAX8POLBTACR1GPR119IRAK4 | |
| SCHEMBL18255941 | 0.84 | POLB (0.46) | PAX8POLBLMNAL3MBTL1BRD4 | |
| SCHEMBL22582966 | 0.84 | NAPRT (0.39) | PAX8POLBTACR1IRAK4LMNA | |
| SCHEMBL29773617 | 0.82 | BRD4 (0.38) | PAX8IRAK4BRD4 | |
| SCHEMBL21084775 | 0.80 | PAX8 (0.46) | PAX8POLBIRAK4LMNAL3MBTL1 | |
| SCHEMBL20839016 | 0.80 | PAX8 (0.36) | PAX8POLBTACR1GPR119BRD4 | |
| SCHEMBL840145 | 0.79 | METAP1 (0.37) | HSD17B1STSP2RX7LMNAL3MBTL1 | |
| SCHEMBL1718618 | 0.79 | ALDH1A1 (0.39) | PAX8POLBLMNAL3MBTL1 | |
| SCHEMBL3881812 | 0.78 | GPBAR1 (0.47) | GPBAR1TACR1MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111278840-B | Pyrrolo [2,3-B ] pyridine compounds and their use for the treatment of cancer | 癌症研究科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-09-20 | — | — | US | disclosed |
| CN-111278840-A | Pyrrolo [2, 3-B ] pyridine compounds and their use for treating cancer | 癌症研究科技有限公司 | 2020-06-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | PDXK, CCNK, CDC42BPB | HSD17B1 2088/4885STS 2945/4885PAX8 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.